Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 80

Results For "clinical"

2985 News Found

Novo Nordisk taps Replicate Bioscience’s srRNA platform for obesity
News | August 31, 2025

Novo Nordisk taps Replicate Bioscience’s srRNA platform for obesity

Replicate will receive research funding and could potentially receive up to approximately US$550 million


FDA suspends Valneva’s license of chikungunya vaccine IXCHIQ in US
Drug Approval | August 31, 2025

FDA suspends Valneva’s license of chikungunya vaccine IXCHIQ in US

The sudden subsequent decision to suspend IXCHIQ is based on updated VAERS data


FDA approves Novavax's Nuvaxovid 2025-2026 formula for prevention of COVID-19
Drug Approval | August 31, 2025

FDA approves Novavax's Nuvaxovid 2025-2026 formula for prevention of COVID-19

Nuvaxovid is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season


Lilly's Verzenio scores first OS improvement in breast Cancer
News | August 30, 2025

Lilly's Verzenio scores first OS improvement in breast Cancer

Treatment with Verzenio also resulted in sustained invasive disease-free survival and distant relapse-free survival benefit


Accro Bioscience and Fosun Pharma ink agreement for TYK2/JAK1 Inhibitor in Greater China
News | August 30, 2025

Accro Bioscience and Fosun Pharma ink agreement for TYK2/JAK1 Inhibitor in Greater China

Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)


Lilly's oral GLP-1 orforglipron succeeds in Phase 3 trial
News | August 29, 2025

Lilly's oral GLP-1 orforglipron succeeds in Phase 3 trial

Triggering global regulatory submissions this year for the treatment of obesity


Zydus Therapeutics reports positive phase-3 results in rare liver disease
News | August 29, 2025

Zydus Therapeutics reports positive phase-3 results in rare liver disease

Saroglitazar was generally well tolerated, with overall adverse events generally balanced between Saroglitazar-treated and placebo-treated patients


Lighthouse receives $49.2 million NIA grant to advance phase 2 study of Alzheimer’s disease
News | August 28, 2025

Lighthouse receives $49.2 million NIA grant to advance phase 2 study of Alzheimer’s disease

LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis


argenx reports positive phase 3 ADAPT SERON results of VYVGART in AChR-Ab seronegative gMG
News | August 28, 2025

argenx reports positive phase 3 ADAPT SERON results of VYVGART in AChR-Ab seronegative gMG

VYVGART was well tolerated, with a safety profile consistent with prior studies in AChR-Ab seropositive gMG and other indications